PMID- 29862649
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 20
IP  - 10
DP  - 2018 Oct
TI  - Contribution of basal and postprandial hyperglycaemia in type 2 diabetes patients 
      treated by an intensified insulin regimen: Impact of pump therapy in the OPT2mise 
      trial.
PG  - 2435-2441
LID - 10.1111/dom.13398 [doi]
AB  - AIMS: The relative contribution of basal hyperglycaemia (BHG) and postprandial 
      hyperglycaemia (PPHG) in type 2 diabetes patients treated with multiple daily 
      injections (MDI) of insulin is poorly documented. In this study, the BHG and PPHG 
      of patients from the OPT2mise study who were initially treated with MDI were 
      assessed before randomization and again after 6 months of continuous subcutaneous 
      insulin infusion (CSII). MATERIALS AND METHODS: Blinded continuous glucose 
      monitoring (CGM) data were collected in 259 MDI patients after completion of an 
      8-week run-in period. The hyperglycaemic area under the curve (AUC) during the 
      24-hour basal period (AUC-B) and the postprandial period (AUC-P) were compared 
      with analysis of variance based on contribution to total hyperglycaemia in HbA1c 
      groups (Group 1, <8%; Group 2, 8%-8.4%; Group 3, 8.5%-8.9%; Group 4, 9%-9.4%; 
      Group 5, >/=9.5%). Changes in AUC-B and AUC-P were assessed after 6 months of pump 
      therapy in 131 randomized participants with available CGM recordings. RESULTS: In 
      patients undergoing MDI therapy, AUC-B was 21.6% to 54.8% lower in Group 4 to 1 
      (P = .0138 and P = .0002, respectively) in comparison to Group 5. In contrast, 
      AUC-P did not differ among HbA1c groups (P = .1009). HbA1c correlated with AUC-B, 
      but not with AUC-P. After switching to CSII, AUC-B and AUC-P decreased by 21% and 
      17%, respectively. When comparing responders with non-responders to CSII therapy, 
      no between-group differences were observed in AUC-B and AUC-P. CONCLUSIONS: Basal 
      hyperglycaemia is the major determinant of overall exposure to hyperglycaemia in 
      type 2 diabetes with MDI failure.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Reznik, Yves
AU  - Reznik Y
AUID- ORCID: 0000-0002-6267-8058
AD  - Department of Endocrinology and Diabetology, Cote de Nacre Regional Hospital 
      Center, Caen, France.
AD  - University of Caen Basse-Normandie, Medical School, Caen, France.
FAU - Habteab, Aklilu
AU  - Habteab A
AD  - Medtronic Bakken Research Center, Maastricht, The Netherlands.
FAU - Castaneda, Javier
AU  - Castaneda J
AD  - Medtronic Bakken Research Center, Maastricht, The Netherlands.
FAU - Shin, John
AU  - Shin J
AD  - Medtronic Diabetes, Northridge, California.
FAU - Joubert, Michael
AU  - Joubert M
AD  - Department of Endocrinology and Diabetology, Cote de Nacre Regional Hospital 
      Center, Caen, France.
AD  - University of Caen Basse-Normandie, Medical School, Caen, France.
LA  - eng
GR  - Medtronic International Trading Sarl, Tolochenaz, Switzerland. The study was 
      sponsored by Medtronic International Trading Sarl, Tolochenaz, 
      Switzerland./International
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20180706
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/drug effects/metabolism
MH  - Blood Glucose Self-Monitoring/instrumentation/methods/standards
MH  - Calibration
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Drug Substitution
MH  - Female
MH  - Glycated Hemoglobin/drug effects/metabolism
MH  - Humans
MH  - Hyperglycemia/complications/*drug therapy
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Insulin/*administration & dosage
MH  - *Insulin Infusion Systems/standards
MH  - Male
MH  - Middle Aged
MH  - Postprandial Period/drug effects
OTO - NOTNLM
OT  - basal hyperglycaemia
OT  - insulin pump
OT  - multiple daily injections
OT  - postprandial hyperglycaemia
OT  - type 2 diabetes
EDAT- 2018/06/05 06:00
MHDA- 2019/01/29 06:00
CRDT- 2018/06/05 06:00
PHST- 2018/01/23 00:00 [received]
PHST- 2018/05/15 00:00 [revised]
PHST- 2018/05/29 00:00 [accepted]
PHST- 2018/06/05 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/06/05 06:00 [entrez]
AID - 10.1111/dom.13398 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2018 Oct;20(10):2435-2441. doi: 10.1111/dom.13398. Epub 2018 
      Jul 6.